Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy

NCT04604834 | Recruiting

• 1 other identifier: OF14-004
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 1

Brief Summary

Neurotrophic keratopathy (NK) is a condition where the cornea loses its capacity to feel pain and touch. This causes a decrease in the production of certain substances that maintain the integrity of the corneal epithelium (the most superficial layer that covers the cornea). As a result, the cornea cannot heal wounds as fast as it should and this could lead to corneal breakdown. This disease is chronic, meaning that it does not resolve quickly, and the treatments commonly used to manage it (such as artificial tears) take a long time to work, which makes it hard to follow doctor's orders. Autologous platelet-rich plasma is a substance that is obtained from the patient's own blood and it may contain those components that are missing in the tears of people with NK. The purpose of this experiment is to find out whether APRP+PFAT is better than APRP alone or PFAT alone in the treatment of NK. Participants will be randomly assigned to one of three groups: one group will start with APRP, other will start with PFAT and another with PFAT+APRP. The participants will receive each treatment for four weeks, and then the subjects will switch groups and use them for four weeks each (12 weeks total). Investigators will evaluate different parameters that will let us know if your condition is improving. These evaluations will be carried out every four weeks from the start to the end of the protocol. In case of intolerance or adverse effects, treatment will be discontinued.

Conditions

Neurotrophic Keratopathy

Keywords

Autologous PRP; Neurotrophic keratopathy; Autologous platelet-rich plasma

Outcome Measures

Primary Outcomes (9)

• Change in corneal staining

  Change in corneal epithelial damage will be measured using corneal staining with fluorescein dye and the NEI grading scale.

  from the beginning of the treatment and every 4 weeks until week 12.

• Change in corneal sensitivity

  Change in corneal sensitivity will be measured using Cochet-Bonnet aesthesiometer.

  from the beginning of the treatment and every 4 weeks until week 12.

• Tear break-up time (TBUT)

  Tear break up time will be assessed using fluorescein dye, measuring break up time in seconds. A result \>10 seconds will be considered normal, a result \<10 seconds will be considered pathological.

  from the beginning of the treatment and every 4 weeks until week 12.

• Ocular Surface Disease Index (OSDI)

  Ocular surface symptoms will be assessed by the Ocular Surface Disease Index (OSDI). The OSDI questionnaire consists of 12 questions that assess dry eye symptoms and their effects on vision related function. The questionnaire is divided in 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients are asked to rate their responses on a 0 to 4 scale where 0 represents "none of the time", 1 "some of the time", 2 "half of the time", 3 "most of the time", and 4 "all of the time". The total score is calculated using the following formula: (\[sum of scores for all questions answered x 100\] / \[total number of questions answered x 4\]). Lower scores represent a better outcome.

  from the beginning of the treatment and every 4 weeks until week 12.

• Tear osmolarity.

  Tear osmolarity is one of tear inflammation biomarkers. Tear osmolarity will be performed with Tear Lab Osmolarity System, a result of 308 milliosmol (mOsm)/L or higher indicates pathological result.

  from the beginning of the treatment and every 4 weeks until week 12.

• Schirmer test with anesthesia

  Tear production will be measured by Schirmer test with anesthesia. The Schirmer test with anesthesia \>15 mm is consider normal.

  from the beginning of the treatment and every 4 weeks until week 12.

• Quality of life questionnaire (National Eye Institute Visual Function Questionnaire-25)

  Quality of life as assessed by the National Eye Institute Visual Function Questionnaire (NEI VFQ-25). The NEI VFQ-25 questionnaire consists of 25 questions that assess the effect of visual impairment on the patient's quality of life. The 25-item questionnaire gives a score on a scale of 0 to 100, where 0 is the worst score and 100 is the best score. Higher scores represent a better outcome.

  from the beginning of the treatment and every 4 weeks until week 12.

• Best corrected visual acuity

  Best corrected visual acuity will be assessed using Snellen cards. Measurements will be converted to LogMar values for statistical analysis.

  from the beginning of the treatment and every 4 weeks until week 12.

• Frequency of adverse events.

  Frequency of adverse events will assessed for security and effectiveness of the treatment during the ophthalmic evaluation.

  from the beginning of the treatment and every 4 weeks until week 12.

Study Arms (3)

PFAT first

EXPERIMENTAL

1 eyedrop of PFAT every 2 hours in study eye.

Other: PFAT first

APRP first

EXPERIMENTAL

1 eyedrop of APRP every 2 hours in study eye.

Other: APRP first

APRP+PFAT first

EXPERIMENTAL

1 eyedrop of PFAT and APRP every 2 hours in study eye.

Other: PFAT first; Other: APRP first

Interventions

PFAT first OTHER

Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

APRP+PFAT first; PFAT first

APRP first OTHER

Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.

APRP first; APRP+PFAT first

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with:
• Neurotrophic keratopathy diagnosed by esthesiometry (defined as central corneal sensitivity ≤ 3cm using Cochet-Bonnet aesthesiometer).
• Corneal erosions.
• Neurotrophic keratopathy secondary to: diabetes mellitus, herpetic keratitis, microbial keratitis sequelae (bacteria, Acanthamoeba, fungi, herpes), limbal stem cell deficiency, chemical or thermic burn sequelae at least 3 months after the accident, ocular trauma with penetrating wound fixed at least 3 months before the trial, surgery carried out at least 3 month before the trial (including keratoplasty, laser in situ keratomileusis, phacoemulsification cataract surgery, extracapsular cataract extraction), adenoviral keratoconjunctivitis resolved at least 3 months the trial.

You may not qualify if:

• Patients diagnosed with:
• Other ocular surface pathology presenting with corneal erosions but without corneal hyposensitivity.
• Corneal epithelial defect with or without corneal hyposensitivity.
• Pregnant women, homeless, migrants.

Sponsors & Collaborators

• Universidad Autonoma de Nuevo Leon: lead
• Hospital Universitario Dr. Jose E. Gonzalez: collaborator

Study Sites (1)

Departamento de Oftalmologia, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

Monterrey, Nuevo León, 64460, Mexico

RECRUITING

Study Officials

• Karim Mohamed-Noriega, M.D.

  Departamento de Oftalmologia, Hospital Universitario Dr. Jose Eleuterio Gonzalez

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Karim Mohamed-Noriega, M.D.

CONTACT

+52 8183469259; karim.mohamednrg@uanl.edu.mx,drkmohamed1@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Masking Details: No blinded study.
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: Subjects will be selected based on inclusion and exclusion criteria. A thorough ophthalmologic evaluation will be carried out before starting any treatment (baseline). Subjects will be randomly assigned to one of the treatment groups and receive the corresponding treatment for 4 weeks. At the end of week 4, subjects will switch treatment groups (crossover) and receive the new treatment for 4 more weeks. At the end of week 8, subjects will start the last treatment for 4 more weeks. Ophthalmologic evaluations will be performed every 4 weeks.

Study Record Dates

• First Submitted: October 15, 2020
• First Posted: October 27, 2020
• Study Start: November 1, 2020
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): December 1, 2027
• Last Updated: May 6, 2026

Record last verified: 2026-05

Locations

ME (1)